Andy Hahn/X
Jun 2, 2025, 12:04
Andy Hahn: Deep, Multi-Omic Analysis of Adjuvant Atezolizumab for ccRCC
Andy Hahn, Genitourinary Medical Oncologist at MD Anderson Cancer Centre, shared a post on X:
“Deep, multi-omic analysis of adjuvant atezolizumab for ccRCC by Sumanta K. Pal and team building on prior KIM-1 studies.
One take away is KIM-1 high, Teff high has longer DFS with atezo than placebo.”
Andy Hahn highlighted new findings from Sumanta K. Pal’s team, showing that patients with high KIM-1 and Teff expression experienced longer disease-free survival when treated with atezolizumab in adjuvant clear cell renal cell carcinoma.
More posts featuring Andy Hahn.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 16, 2025, 20:13
Jul 16, 2025, 17:55
Jul 16, 2025, 17:38
Jul 16, 2025, 17:37
Jul 16, 2025, 17:04
Jul 16, 2025, 16:51
Jul 16, 2025, 16:34